What We DO

 

PharmAla Biotech Business Line

(

MDMA MOLECULE

"
'

MANUFACTURING

Sales to psychedelics companies and researchers

MOLECULES

IP development of manufacturing innovation.

DELIVERY

Novel delivery mechanisms which drive both research, and new standards of care

PharmAla is also focused on exploring new mechanisms of manufacture, including novel crystallization techniques and synthesis of unique molecule profiles, as well as drug development and pre-clinical research into MDMA and its clinical applications.

PharmAla Biotech
Business Line

MDMA MOLECULE

Off-patent, generic

"

MANUFACTURING

Sales to psychedelics companies and researchers

Cashflow withinlor  16 months

MOLECULES

IP development of manufacturing innovation.

Increased efficiency, licensing opportunities

DELIVERY

Novel delivery mechanisms

Patent opportunities, research, new standards of care

New use cases

PharmAla is also focused on exploring new mechanisms of manufacture, including novel crystallization techniques and synthesis of unique molecule profiles, as well as drug development and pre-clinical research into MDMA and its clinical applications.

Potential Clinical Uses of MDMA

PharmAla Biotech is committed to becoming Canada’s first and leading manufacturer of clinical-grade MDMA for research purposes.

In addition to treatment for individual sufferers of PTSD, MDMA is under evaluation as a potential treatment for couples therapy, eating disorders, alcohol addiction, anxiety and depression.

PharmAla’s Board Director, Prof. David Nutt, recently published a study detailing MDMA’s promising potential uses in the treatment of alcohol addiction.*

Numerous researchers have indicated to PharmAla that they are interested in MDMA research, but are unable to move forward due to the extreme difficulty in setting up research in Canada and in securing a supply of clinical-grade product.